Changing The Subject (Part 1): Stop Trying To “Win” The Drug Pricing Debate
This article was originally published in RPM Report
When it comes to pricing, it is worth remembering that the interests of buyers and sellers can never be truly aligned. So rather than trying to “win” the drug pricing debate, the pharmaceutical industry may be better served by steering it into new areas. We plan to propose some big ideas that might work in that direction.
Register for our free email digests: